Aminoglycoside Dosing Interval Calculator
Enter creatinine clearance and optional post-dose serum level to determine the recommended gentamicin/tobramycin dosing interval using the Hartford nomogram.
Patient Parameters
Post-Dose Level (Optional)
Hartford nomogram confirmation: draw level 6–14 h after the first dose.
Educational reference only. All results must be verified by a licensed pharmacist or physician. This tool does not replace clinical judgment or therapeutic drug monitoring.
Enter patient data and click Calculate Interval
Recommended Dosing Interval
Renal Function Estimate
Suggested Starting Dose (7 mg/kg)
Post-Dose Level Evaluation
Monitoring: Draw a serum level 6–14 hours after the first dose. Plot the level and time on the Hartford nomogram to confirm the assigned interval. Re-evaluate interval if renal function changes during therapy.
Summary
Enter creatinine clearance and optional post-dose serum level to determine the recommended gentamicin/tobramycin dosing interval using the Hartford nomogram.
How it works
- Enter patient age, sex, weight, and serum creatinine to estimate CrCl via Cockcroft-Gault.
- The tool maps CrCl to the standard Hartford nomogram interval: ≥60 → q24h, 40–59 → q36h, 20–39 → q48h, <20 → not recommended.
- Optionally, enter a 6–14 hour post-dose serum level drawn after the first dose.
- The post-dose level is compared to the Hartford nomogram zone boundaries for the chosen interval to confirm suitability.
- Results display the recommended interval, the Cockcroft-Gault CrCl, and any monitoring guidance.
Use cases
- Select the starting q24h/q36h/q48h interval for a new extended-interval gentamicin order.
- Confirm the dosing interval using the Hartford nomogram after drawing a 6–14h post-dose level.
- Adjust gentamicin or tobramycin interval when renal function changes mid-course.
- Educate pharmacy students on applying the Hartford nomogram in clinical practice.
- Cross-check an interval recommendation before signing a pharmacokinetic consult.
- Screen whether a patient with moderate renal impairment is a candidate for once-daily aminoglycoside therapy.